These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 18558668)
1. Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. Cheng LS; Amaro RE; Xu D; Li WW; Arzberger PW; McCammon JA J Med Chem; 2008 Jul; 51(13):3878-94. PubMed ID: 18558668 [TBL] [Abstract][Full Text] [Related]
2. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling. Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092 [TBL] [Abstract][Full Text] [Related]
3. Comment on "Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)". Rungrotmongkol T; Malaisree M; Udommaneethanakit T; Hannongbua S Biophys Chem; 2009 Apr; 141(1):131-2; author reply 133. PubMed ID: 19231807 [No Abstract] [Full Text] [Related]
4. Identification of potential inhibitors of H5N1 influenza A virus neuraminidase by ligand-based virtual screening approach. Karthick V; Ramanathan K; Shanthi V; Rajasekaran R Cell Biochem Biophys; 2013 Jul; 66(3):657-69. PubMed ID: 23306969 [TBL] [Abstract][Full Text] [Related]
5. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus. Du QS; Wang SQ; Chou KC Biochem Biophys Res Commun; 2007 Oct; 362(2):525-31. PubMed ID: 17707775 [TBL] [Abstract][Full Text] [Related]
6. Binding mechanism of H5N1 influenza virus neuraminidase with ligands and its implication for drug design. Gong K; Li L; Wang JF; Cheng F; Wei DQ; Chou KC Med Chem; 2009 May; 5(3):242-9. PubMed ID: 19442214 [TBL] [Abstract][Full Text] [Related]
8. Dynamic behavior of avian influenza A virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues. Udommaneethanakit T; Rungrotmongkol T; Bren U; Frecer V; Stanislav M J Chem Inf Model; 2009 Oct; 49(10):2323-32. PubMed ID: 19780597 [TBL] [Abstract][Full Text] [Related]
9. Virtual screening pipeline and ligand modelling for H5N1 neuraminidase. D'Ursi P; Chiappori F; Merelli I; Cozzi P; Rovida E; Milanesi L Biochem Biophys Res Commun; 2009 Jun; 383(4):445-9. PubMed ID: 19371724 [TBL] [Abstract][Full Text] [Related]
10. Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses. Singh A; Soliman ME Drug Des Devel Ther; 2015; 9():4137-54. PubMed ID: 26257512 [TBL] [Abstract][Full Text] [Related]
11. Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase. Xie Y; Xu D; Huang B; Ma X; Qi W; Shi F; Liu X; Zhang Y; Xu W J Med Chem; 2014 Oct; 57(20):8445-58. PubMed ID: 25255388 [TBL] [Abstract][Full Text] [Related]
12. Combinatorial design of avian influenza neuraminidase inhibitors containing pyrrolidine core with a reduced susceptibility to viral drug resistance. Rungrotmongkol T; Udommaneethanakit T; Frecer V; Miertus S Comb Chem High Throughput Screen; 2010 Mar; 13(3):268-77. PubMed ID: 20015013 [TBL] [Abstract][Full Text] [Related]
13. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Collins PJ; Haire LF; Lin YP; Liu J; Russell RJ; Walker PA; Skehel JJ; Martin SR; Hay AJ; Gamblin SJ Nature; 2008 Jun; 453(7199):1258-61. PubMed ID: 18480754 [TBL] [Abstract][Full Text] [Related]
14. Molecular dynamics simulation of oseltamivir resistance in neuraminidase of avian influenza H5N1 virus. Shu M; Lin Z; Zhang Y; Wu Y; Mei H; Jiang Y J Mol Model; 2011 Mar; 17(3):587-92. PubMed ID: 20517627 [TBL] [Abstract][Full Text] [Related]
15. Discovery andsynthesis of novel benzoylhydrazone neuraminidase inhibitors. Fu SK; Cheng LP Bioorg Med Chem Lett; 2024 Jun; 105():129743. PubMed ID: 38608962 [TBL] [Abstract][Full Text] [Related]
16. Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1. Malaisree M; Rungrotmongkol T; Decha P; Intharathep P; Aruksakunwong O; Hannongbua S Proteins; 2008 Jun; 71(4):1908-18. PubMed ID: 18175324 [TBL] [Abstract][Full Text] [Related]
17. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA). Mitrasinovic PM Biophys Chem; 2009 Mar; 140(1-3):35-8. PubMed ID: 19117662 [TBL] [Abstract][Full Text] [Related]
18. Discovery of novel thiophene derivatives as potent neuraminidase inhibitors. Zhong ZJ; Hu XT; Cheng LP; Zhang XY; Zhang Q; Zhang J Eur J Med Chem; 2021 Dec; 225():113762. PubMed ID: 34411893 [TBL] [Abstract][Full Text] [Related]
19. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Russell RJ; Haire LF; Stevens DJ; Collins PJ; Lin YP; Blackburn GM; Hay AJ; Gamblin SJ; Skehel JJ Nature; 2006 Sep; 443(7107):45-9. PubMed ID: 16915235 [TBL] [Abstract][Full Text] [Related]
20. Pharmacophore-Based Virtual Screening for Identification of Novel Neuraminidase Inhibitors and Verification of Inhibitory Activity by Molecular Docking. Batool S; Mushtaq G; Kamal W; Kamal MA Med Chem; 2016; 12(1):63-73. PubMed ID: 26152143 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]